Diligence memo · auto-generated · as of July 2, 2026

aMBR Genomics, Inc.

aMBR Genomics, Inc. has raised $1.1M over 1 round; too few niche peers to rank its valuation yet.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

aMBR Genomics, Inc. operates in Biotech, based in MADISON.

Sub-sector tags: biotech.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

aMBR Genomics, Inc. has raised $1.1M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $1.1M on 2025-10-21.

Most recent recorded round closed around 2025-10-21.

Valuation (modeled)modeled

Provath models aMBR Genomics, Inc. at approximately $2.6M (range $792K–$4.8M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Too few comparable companies in this niche to rank the valuation fairly yet.

Financing rhythm & timingmixed

Last raise 8 mo ago; this sector typically re-raises about every 11 months.

Raising on or ahead of the sector's normal rhythm.

Comparablesmixed

Capital scale ranks ahead of 74% of Biotech peers (233 compared).

Modeled value ranks above 71% of those peers.

Closest niche peers: Primary Bioscience, Inc..

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.